This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Anderson, I. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Anderson, I. M.
Advances in Psychiatric Treatment (2003) 9: 11-20
© 2003 The Royal College of Psychiatrists

Drug treatment of depression: reflections on the evidence

Ian M. Anderson

Ian Anderson is a senior lecturer and honorary consultant psychiatrist at Manchester Royal Infirmary (University of Manchester, Neuroscience and Psychiatry Unit, Room G809, Stopford Building, Oxford Road, Manchester M13 9PT, UK. Tel: 0161 275 7428; fax: 0161 275 7429; e-mail: ian.anderson{at}man.ac.uk). His research interests are in the psychopharmacology of affective disorders and in evidence-based psychiatry.

Guidelines are readily available for the treatment of depression, and more recent ones are explicitly evidence-based. Their core messages vary little but they tend to minimise uncertainties and gloss over difficult areas. This article examines three areas of uncertainty: the thresholds of severity and, for milder depression, the duration of illness for which antidepressants are more effective than placebo; the next step in drug treatment when a patient has failed to respond adequately to a first antidepressant; and how long continuing on antidepressants should be recommended in relation to individual patients’ needs. It is concluded that the uncertainties in relation to treating individual patients are a combination of lack of evidence and individual patient factors but there is also an intrinsic uncertainty that will continue to require good clinical judgement.




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
J Psychopharmacol, June 1, 2008; 22(4): 343 - 396.
[Abstract] [PDF]

Home page
 Br. J. PsychiatryHome page
H. G. RUHE, J. HUYSER, J. A. SWINKELS, and A. H. SCHENE
Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: Systematic review
The British Journal of Psychiatry, October 1, 2006; 189(4): 309 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
M. Shooter
Dancing with the Devil? A personal view of psychiatry's relationships with the pharmaceutical industry
Psychiatr. Bull., March 1, 2005; 29(3): 81 - 83.
[Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
R. Baldwin and R. Wild
Management of depression in later life
Adv. Psychiatr. Treat., March 1, 2004; 10(2): 131 - 139.
[Abstract] [Full Text] [PDF]